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Introduction
Stem cell factor (SCF) is a polyfunctional cytokine that plays a key role in the regulation of hematopoiesis, acting as a regulator at various stages of this process. SCF promotes the survival (Domen and Weissman, 2000) , proliferation (Leary et al., 1992; Tsai et al., 1991) , mobilization (Fleming et al., 1993) and adhesion (Levesque et al., 1995) of hematopoietic stem cells and their progenitors. The cytokine is also involved in the development and function of other cell lineages, including melanocytes and germ cells (Sette et al., 2000) . SCF triggers its biological effects upon binding to its receptor c-kit, a member of the type III receptor kinase family (Bazan, 1991; Hubbard and Till, 2000; Yarden et al., 1987) .
SCF, also named kit ligand, mast cell growth factor or steel factor was first identified and characterized in the early 1990s (Huang et al., 1990; Williams et al., 1990; Zsebo et al., 1990) .
The different names given to this growth factor reflect its multiple functions, displaying unique and nonredundant activities on primitive progenitor/stem cells (Lyman and Jacobsen, 1998; Sette et al., 2000) . In vivo as well as in vitro, SCF synergizes with a number of other cytokines such as granulocyte colony-stimulating factor (Bernstein et al., 1991) , granulocytemacrophage colony-stimulating factor (Witte, 1990) , erythropoietin (EPO) (Brugger et al., 1995) , Thrombopoietin (TPO) (Kobayashi et al., 1996) or interleukin (Rennick et al., 1995) .
Naturally occurring SCF exists as membrane-bound and soluble isoforms as a result of alternative RNA-splicing and proteolytic processing (Arakawa et al., 1991; Lu et al., 1991) .
The soluble protein is heavily N-and O-glycosylated, has extensive secondary structures and is dimeric (non covalently associated) under non-denaturating conditions (Arakawa et al., 1991; Langley et al., 1992; Zhang et al., 2000) . The presence or absence of the carbohydrate moieties does not influence the biological activity (Flanagan and Leder, 1990; Zsebo et al., 1990) , whereas the two intramolecular disulfide bonds of SCF are essential (Jones et al., 1996) .
Soluble murine SCF (mSCF) exhibits a high cross-species activity on human cells, while the human protein is about 800-fold less active on murine cells than mSCF (Martin et al., 1990) .
The cross-species activity of mSCF makes it more versatile for different applications than human SCF and is therefore chosen as target in this study. SCF is -although expensivefrequently used in hematopoietic stem and progenitor cell growth and expansion. For this reason it is used in clinical settings, e.g. in gene therapy to stimulate and expand human -4 -CD34+ cells (Bodine et al., 1994) or for the treatment of aplastic anemia (Smith et al., 2001) .
Furthermore, SCF is widely used in hematopoietic stem cell culture for research purposes.
Production and purification of recombinant soluble SCF have been previously reported.
Human and rat SCF were expressed in E. coli, in COS-7 cells and in CHO cells (Arakawa et al., 1991; Flanagan and Leder, 1990; Langley et al., 1992; Martin et al., 1990) . The simultaneous renaturation and purification of E. coli-derived human SCF has been described as well (Lili et al., 2006; Wang et al., 2008) . Furthermore, several fusion constructs of human and murine SCF have been reported (diphtheria toxin-SCF (Potala and Verma, 2010) , TPO-SCF (Su et al., 2006) , TPO-SCF-thioredoxin fusionprotein (Zang et al., 2007) and TRX-SCF (LaVallie et al., 1993) .
A frequent problem of SCF production in E coli is the formation of inclusion bodies. To date, SCF has exclusively been expressed in E. coli as insoluble and inactive aggregates (Arakawa et al., 1991; Langley et al., 1994; Langley et al., 1992; Lili et al., 2006; Martin et al., 1990; Wang et al., 2008; Wang et al., 2004) . The current strategy for recovery of active SCF from inclusion bodies includes solubilization, oxidation and refolding steps (Wang et al., 2008) .
This time-consuming process of protein renaturation can be overcome by the method presented in this work. For the first time, we herein report the production of soluble bioactive mSCF, applying a fusion protein approach with thioredoxin (TRX) (LaVallie et al., 1993) .
Being a potent enhancer of the solubility of eukaryotic proteins (LaVallie et al., 1993; Takashi et al., 1995) , bacterial TRX actively promotes the disulfide bond formation of appropriate substrate molecules (Stewart et al., 1998) . TRX is believed to act as "molecular chaperone", mediating the formation of its fusion partner in the soluble form as the latter emerges from the ribosome (LaVallie et al., 1993) .
In order to obtain bioactive SCF, the purification of the soluble fusion protein was followed by subsequent cleavage with Tobacco Etch Virus (TEV) protease, giving rise to mature mSCF (18 kDa). After final purification, the cytokine was tested for bioactivity (MTT analogous assay, long-term proliferation assay) utilizing the human megakaryocytic cell line M-07e.
Avoiding inclusion body formation, the results of the presented work provide an efficient production procedure for mSCF.
Materials and Methods

2.1
Design and synthesis of expression vector pET32b-trx-his-tev-mSCF 
SDS-PAGE
For SDS-PAGE analysis, polyacrylamide gels with samples from crude cell lysates were stained with Coomassie Brilliant Blue. Gels with purified proteins from different purification steps were stained with silver in order to directly apply the samples to the gel (without any concentration steps).
Affinity purification of TRX-mSCF fusion protein
In order to purify the fusion protein via immobilized metal-affinity chromatography (IMAC), (Ball, 1986) with BSA as standard was performed. Gel-Pro Analyzer 6.0 software was used to evaluate the data. The IMAC purification from the crude lysate was carried out several times and from different batches.
Proteolytic cleavage of TRX-mSCF fusion protein
The purified fusion protein was cleaved with TEV protease (AcTEV, Invitrogen, Darmstadt, Germany) at 4 °C for 40 h (the experiment was repeated manifold with different batches of purified fusion protein). The cleavage was performed following the manufacturer´s instructions except for application of only 5 units protease per 20 µg fusion protein (which accounts for half the amount of protease than suggested by the manufacturer).
Purification of mSCF after proteolytic cleavage
Prior to final purification, the protein mixture was dialysed against PBS buffer (10 mmol/L Na 2 HPO 4 •2 H 2 O, 2 mmol/L KH 2 PO 4 , pH 7.4, 137 mmol/L NaCl, 2.7 mmol/L KCl) at 7 °C for 24 h, using dialysis tubing with a molecular weight cut off of 12-14 kDa (Visking dialysis membranes, Size 2, Medicell International Ltd, London, UK). For preparation of the tubing, the latter was treated with a solution of 2 % (w/v) NaHCO 3 and 1 mmol/L EDTA for 30 min at 80 °C and finally washed with distilled water.
To carry out a second IMAC purification, a Sartobind IDA 75 membrane adsorber module (Sartorius-Stedim Biotech) was charged with Zn 2+ (0.5 mol/ L in 100 mmol/L NaAc, pH 4.5, 500 mmol/L NaCl) and equilibrated with PBS buffer (10 mmol/L Na 2 HPO 4 •2 H 2 O, 2 mmol/L KH 2 PO 4 , pH 7.4, 137 mmol/L NaCl, 2.7 mmol/L KCl). After loading the membrane with the dialysed cleavage batch, the latter was properly washed with PBS buffer. Since the target protein had lost its His-tag upon proteolytic cleavage, mSCF was found in the flow-through fractions, as determined by SDS-PAGE. Qualitative and quantitative analysis of pooled mSCF containing fractions were performed using an ELISA kit (mouse SCF ELISA kit, Ray Biotech
Inc., Cologne, Germany) according to manufacturer´s instructions. This second IMAC purification was performed several times with different cleavage batches.
To detect endotoxin levels, the mSCF protein solution was analysed by LAL Test (Endosafe-PTSTM, Charles River Laboratories, Boston, MA, USA). Finally, the mSCF protein solution was filtered (0.2 µm Minisart sterile filter, Sartorius-Stedim Biotech) and stored in aliquots at -20 °C.
Determination of TRX-mSCF fusion protein concentration in crude lysate
In order to quantify the amount of TRX-mSCF fusion protein in the total cell protein, the crude lysate was analyzed by densitometry using BSA as standard. For evaluation of the data Gel-Pro Analyzer 6.0 software was used. The amount of total protein in the crude lysate was determined using the Bradford assay with BSA as standard.
Biological testing
Cell culture
All bioactivity assays were carried out using the human megakaryocytic cell line M-07e
(DMSZ, Braunschweig, Germany) (Erickson-Miller et al., 1993; Hendrie et al., 1991) . 
Short-term proliferation
After IMAC-purification of TRX-mSCF, the mixture of the fusion protein and its truncated version was filtered (0.2 µm Minisart sterile filter, Sartorius-Stedim Biotech). To determine the concentration of TRX-mSCF in the mixture, densitometric scanning results of a Coomassie stained SDS-PAGE were evaluated.
The biological activity of TRX-mSCF and purified mSCF in comparison to SCF comm was investigated performing a cell proliferation assay with soluble formazan (CellTiter96 AQ ueous One Solution Cell Proliferation Assay, Promega, Mannheim, Germany), according to manufacturer´s instructions (quintuplicates for each sample). Being suitable for suspension cells, the principle of this assay is analogous to MTT assay. All cytokines were added in the same concentration (520 ng/ mL).
Long-term proliferation
M-07e cells were washed three times with PBS (Dulbecco´s PBS without Ca/Mg, PAA Laboratories GmbH) via centrifugation (311 g, 10 min), resuspended in fresh culture medium and seeded to a final concentration of 4.5 x 10 5 cells/ mL. SCF comm was added in concentrations of 520 ng/ mL and 260 ng/ mL; purified mSCF was added in concentrations of 417 ng/ mL, 83 ng/ mL and 42 ng/ mL. Each cytokine concentration was investigated in triplicates. M-07e cells were passaged every two to three days over a period of about five weeks by reseeding with a cell density of 4.5 x 10 5 cells/ mL and addition of cytokines in the concentrations defined above. Cell numbers were determined using hemocytometer counts. with Roti-Histokitt (Roth, Karlsruhe, Germany), covered with a thin glass plate and dried. In order to examine the cell morphology, the slides were magnified by using a high resolving microscope (Zeiss AxioImager.M1, Göttingen, Germany).
Determination of EC 50
To evaluate the EC 50 value of purified mSCF in comparison to SCF comm. , a cell proliferation assay with soluble formazan (CellTiter96 AQ ueous One Solution Cell Proliferation Assay, Promega) was performed according to manufacturer´s protocol. Based on the obtained data for a series of different concentrations of purified mSCF and SCF comm , both EC 50 values were finally calculated (Alexander et al., 1999) .
Results and Discussion
Construction of expression vector
The successful assembly of the expression vector pET32b-trx-his-tev-mSCF was verified by sequencing (see Fig. 1A and material and methods for details). The TEV cleavage site, located between the TRX and the mSCF sequences, enables the release of mature mSCF from the TRX-mSCF fusion protein, leaving the TRX and the His-tag behind (Fig. 1B) . Expression of the resulting fusion protein TRX-mSCF (with a predicted molecular weight of 32 kDa) is driven by the strong T7 promoter, which is specific only to T7 RNA polymerase. The latter is produced by the bacterial host strain BL21 (DE3) via IPTG-induction.
Expression of TRX-mSCF
For expression of TRX-mSCF fusion protein the transformed E. coli BL21 (DE3) cells were cultivated in 200 mL LB medium in shake flasks at 37 °C. Since it has been reported that a reduction of cultivation temperatures eases the solubility of proteins (Schein, 1989) , other temperatures (30 °C and 23 °C) were tested as well. Although TRX-mSCF was soluble at all examined temperatures (data not shown), the cultivation was carried out at 37 °C to reduce the overall cultivation time.
As revealed by SDS-PAGE analysis, TRX-mSCF fusion protein (32 kDa) mainly exists in the soluble fraction of the bacterial cell lysate (Fig. 2) . Inclusion body formation, as might be seen in the insoluble fraction of the cell lysate, is hardly observed. Up to the present, SCF expression in E. coli has always led to insoluble inclusion bodies (Langley et al., 1992; Lili et al., 2006; Potala and Verma, 2010; Su et al., 2006; Wang et al., 2008) , thus the formation of soluble TRX-mSCF is obviously due to the TRX presence.
According to densitometric scanning results and evaluation of Bradford assay data, TRXmSCF accumulated up to 35 % of the total bacterial proteins.
Purification of TRX-mSCF
For an IMAC purification of TRX-mSCF, the soluble fraction of the cell lysate was processed (Fig. 3A) . According to Western Blot analysis using antibody against His-tag (data not shown), both proteins possess a His-tag and can therefore not be separated by IMAC technique. Experiments examining the temporal stability of TRX-mSCF in the soluble fraction of the cell lysate indicate a sensitivity of TRX-mSCF to bacterial proteases (Fig. 3B) . However, none of the different protease inhibitor cocktails applied was able to prevent the degradation (data not shown). Therefore no protease inhibitors were used during the production process of mSCF. To keep degradation at a minimum, the downstream processing was carried out as quickly as possible.
In order to release mature mSCF via proteolytic cleavage of TRX-mSCF with TEV protease, the mixture of TRX-mSCF and its truncated version was used. After 40 h at 4 °C the starting material was digested for the most part (Fig. 4 , Lane 3) to result in the His-tagged TRX (14 kDa) and the mSCF protein (18 kDa). Extending the reaction time did not drive the cleavage to completion either (data not shown). The truncated version of TRX-mSCF was cleaved as well, giving rise to an additional protein which is slightly smaller than the Histagged TRX (Fig. 4, lanes 3 and 4) . Because of the absence of this protein in the final purified protein solution (Fig. 4, lane 5) , which was obtained via IMAC purification (see section 3.4), we assume that this additional protein processes a His-tag as well. Although the formation of the truncated version of TRX-mSCF could not be prevented, this protein and its cleavage product could be finally separated from the target protein mSCF.
A frequent problem of the fusion protein approach is the potential aggregation of the target protein after cleavage from their solubility tag (Esposito and Chatterjee, 2006) . Therefore it is noteworthy that the target protein of this study, mSCF, remained soluble even after separation from the TRX-tag.
Purification of mSCF
Prior to the last purification step, the cleavage batch was dialyzed against PBS and subsequently loaded on a membrane adsorber module with immobilized Zn 2+ . Since the target protein lost its His-tag upon proteolytic cleavage, mSCF was found in the flow-through fractions, whereas TRX and the undigested TRX-mSCF fusion protein bound to the membrane. Via this IMAC purification step, the remains of the truncated version of mSCF and its cleavage product were eliminated as well. Finally, a highly purified mSCF was obtained (Fig. 4 , Lane 5), estimating the purity of the final product being 95 % by SDS-PAGE and silver staining. As determined by LAL test, the amount of endotoxins of purified mSCF was tolerably low (< 14 EU/ µg).
Biological testing
Short-term proliferation assay
In order to examine the biological activity of purified mSCF and uncleaved TRX-mSCF (as mixture of the IMAC-purified fusion protein and its truncated version), the recombinant proteins were compared to SCF comm . As a test system, we chose the well characterized M-07e
cells. This megakaryocytic human cell line is highly growth factor-dependent and proliferates when stimulated by certain cytokine cocktails (Hendrie et al., 1991) as well as by a number of individual cytokines, including SCF (Erickson-Miller et al., 1993) . M-07e cells are therefore highly suitable to prove the bioactivity of purified mSCF.
The results of the short-time proliferation experiment are illustrated in Fig. 5 , displaying that the activity of purified mSCF is comparable to SCF comm. . Although the fusion protein TRXmSCF is less active than purified mSCF, its bioactivity is noteworthy.
Long-term proliferation assay
Given the results of the short-term proliferation assay, the bioactivity of purified mSCF was investigated in a long-term proliferation experiment with M-07e cells. As negative control, M-07e cells were cultured in the absence of the cytokine; SCF comm was utilized as standard.
The results of this assay are illustrated in Fig. 6A , proving the purified mSCF being bioactive over a time period of about five weeks. The distinct cytokine dependence of M-07e cells is clearly marked by the death of the cells in the negative control after a short time of cultivation. Cell numbers of cultures with 42 ng/ mL and 84 ng/ mL of purified mSCF initially dropped dramatically, but then stabilized to minor, but constant proliferation rates.
Comparison of purified mSCF in a concentration of 417 ng/ mL and both positive controls (520 ng/ mL and 260 ng/ mL) highlights the slight superiority of the purified cytokine. This assumption is confirmed by determination of the respective EC 50 values (Fig. 6B) , yielding in 168 ng/ mL for the purified mSCF and 241 ng/ mL for SCF comm . We assume the slightly reduced activity of SCF comm being a result of the packaging and handling of the commercial protein.
Morphology of M-07e cells
In addition to the cell numbers determined during the long-term proliferation, the biological properties of purified mSCF were further tested via examination of the cell morphology of M07e cells after the long-term assay. For this purpose M-07e cells were immobilized via cytospin centrifugation and subsequently stained according to the Pappenheim method. M-07e cells cultivated with 520 ng/ mL SCF comm (Fig. 7A ) and 417 ng/ mL purified mSCF (Fig. 7B) look both equally vital, exhibiting the normal appearance of this cell type (Avanzi et al., 1988) . This finding confirms the results already obtained for the cells numbers in the longterm assay (Fig. 6 ). In contrast, M-07e cells cultivated with 42 ng/ mL purified mSCF (Fig.   7C ) show an irregular shape and lots of cell debris. This observation is also in agreement with the results of the long-term assay, indicating a mSCF deficiency compared to the amount requested for optimal cell growth.
Conclusions
Expression of eukaryotic proteins in bacteria is often the most efficient method to generate proteins for drug discovery efforts. To date, the growth factor SCF, playing a major role at various stages of hematopoiesis, has only been expressed in E. coli as insoluble and inactive inclusion bodies. In this report, we describe for the first time the preparation of soluble mSCF from recombinant E. coli and therefore circumvent the time-consuming renaturation of insoluble aggregates.
An expression vector containing genes for mature mSCF, TRX, a His-tag and a TEV cleavage site enabled the soluble expression of the fusion protein TRX-mSCF in E. coli. After IMAC purification, TRX-mSCF was cleaved by TEV protease in order to release mSCF. Following the final purification via second IMAC, the cytokine was successfully tested for bioactivity (short-term and long-term expansion of the hematopoietic cell line M-07e). Referrering to the short-term proliferation experiment, the uncleaved fusion protein TRX-mSCF showed a significant bioactivity as well, even though it was less active than purified mSCF.
To conclude, avoiding inclusion body formation we presented a straightforward protocol to produce soluble, bioactive mSCF from E. coli. 
Fig. 4
Silver stained 12% SDS-PAGE analysis of TRX-mSCF cleavage and final purification to obtain pure mSCF. Lane 1, molecular weight marker Fermentas SM0661 (M=marker); Lane 2, starting material for proteolytic cleavage consisting of TRX-mSCF and its truncated version (sm=starting material); Lane 3, result of proteolytic cleavage: TRX (14 kDa), mSCF (18 kDa) and remains of TRX-mSCF (cleav=cleaved); Lane 4, cleavage batch after dialysis (dia=dialyzed); Lane 5, mSCF after final IMAC purification (mSCF).
Fig. 5
Results of short-term proliferation assay. M-07e cells were stimulated by 520 ng/ mL of SCF comm , mSCF and TRX-mSCF (as a mixture with its truncated version). As negative control, cells were cultured in the absence of cytokines.
